Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Comparison of KRAS genotype: therascreen assay vs. LNA-mediated qPCR clamping assay.

Clinical colorectal cancer - 1 Sept 2013

Chang Shao-Chun, Denne Jonathan, Zhao Luping, Horak Christine, Green George, Khambata-Ford Shirin, Bray Christopher, Celik Ilhan, Van Cutsem Eric, Harbison Christopher

Abstract excerpt

BACKGROUND: Kirsten rat sarcoma virus (KRAS) wild-type status determined using a locked nucleic acid (LNA)-mediated quantitative polymerase chain reaction (qPCR) clamping assay (LNA assay) predicted response to therapy in the CRYSTAL (Cetuximab Combined With Irinotecan in First-Line Therapy for Metastatic Colorectal Cancer) study. A companion KRAS diagnostic tool has been developed for routine clinical use...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to Camptothecin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cetuximab

Share to Fluorouracil

Share to Irinotecan

Share to Leucovorin

Share to Oligonucleotides

Share to ras Proteins

Source

Identifiers

PMID: 23978462
DOI: 10.1016/j.clcc.2013.05.001

Genes

KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Comparison of KRAS genotype: therascreen assay vs. LNA-mediated qPCR clamping assay.PMID 23978462Read ↗

KRAS mutation analysis by PCR: a comparison of two methods.Semantic proximity Read ↗

Validation of companion diagnostic for detection of mutations in codons 12 and 13 of the KRAS gene in patients with metastatic colorectal cancer: analysis of the NCIC CTG CO.17 trial.Semantic proximity Read ↗

Novel Approach for Clinical Validation of the cobas KRAS Mutation Test in Advanced Colorectal Cancer.Semantic proximity Read ↗

Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer.Semantic proximity Read ↗

The frequency of KRAS mutation detection in human colon carcinoma is influenced by the sensitivity of assay methodology: a comparison between direct sequencing and real-time PCR.Semantic proximity Read ↗

Analytical and clinical validation of a novel amplicon-based NGS assay for the evaluation of circulating tumor DNA in metastatic colorectal cancer patientsSemantic proximity Read ↗

Performance evaluation comparison of 3 commercially available PCR-based KRAS mutation testing platforms.Semantic proximity Read ↗

KRAS analysis in colorectal carcinoma: analytical aspects of Pyrosequencing and allele-specific PCR in clinical practice.Semantic proximity Read ↗

Optimization of RAS/BRAF Mutational Analysis Confirms Improvement in Patient Selection for Clinical Benefit to Anti-EGFR Treatment in Metastatic Colorectal Cancer.Semantic proximity Read ↗

A PNA-mediated clamping PCR for routine detection of KRAS mutations in colorectal carcinoma.Semantic proximity Read ↗

Clinical utility of KRAS status in circulating plasma DNA compared to archival tumour tissue from patients with metastatic colorectal cancer treated with anti-epidermal growth factor receptor therapy.Semantic proximity Read ↗

Concordance of blood- and tumor-based detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.